{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:35:30Z","timestamp":1770287730031,"version":"3.49.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H30-menneki-shitei-002"],"award-info":[{"award-number":["H30-menneki-shitei-002"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To identify the optimal treatment for rheumatoid arthritis (RA) after the regression of lymphoproliferative disorders (LPDs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The subjects were 232 patients with RA who developed LPD between 2000 and 2017 at seven hospitals participating in the LPD-WG study. Kaplan-Meier and Cox proportional regression analyses were performed to determine the factors associated with the rate of LPD relapse and the retention of biological disease-modifying antirheumatic drugs (bDMARDs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Treatment for RA was resumed in 138 patients after spontaneous regression of LPD after the discontinuation of methotrexate and in 52 patients after chemotherapy for LPD (persistent-LPD). LPD relapses occurred in 23 patients. Not DMARDs use but Hodgkin\u2019s lymphoma was identified as a risk factor for LPD relapse. In 88 RA patients treated with bDMARDs [tocilizumab, 39 patients; abatacept 20 patients; tumor necrosis factor inhibitor, 29 patients], the one-year retention rate was 67.8%. The risk factors for discontinuation of bDMARDs were persistent-LPD, non-diffuse large B-cell lymphomas (non-DLBCL), and a high clinical disease activity index (CDAI). Tocilizumab showed the highest retention rate among bDMARDs, particularly in DLBCL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Although any bDMARD could be used in patients after LPD regression, effectiveness and risk for relapse should be carefully assessed for each LPD subtype.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1080\/14397595.2020.1847775","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T07:13:01Z","timestamp":1604905981000},"page":"41-49","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study"],"prefix":"10.1093","volume":"32","author":[{"given":"Kazuhisa","family":"Nakano","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"},{"name":"Working Group on the Rheumatoid Arthritis-associated Lymphoproliferative Disorders of the Japan College of Rheumatology, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Saito","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"},{"name":"Working Group on the Rheumatoid Arthritis-associated Lymphoproliferative Disorders of the Japan College of Rheumatology, Tokyo, Japan"},{"name":"Tobata General Hospital, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Working Group on the Rheumatoid Arthritis-associated Lymphoproliferative Disorders of the Japan College of Rheumatology, Tokyo, Japan"},{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuntaro","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Working Group on the Rheumatoid Arthritis-associated Lymphoproliferative Disorders of the Japan College of Rheumatology, Tokyo, Japan"},{"name":"Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rintaro","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Fujii","sequence":"additional","affiliation":[{"name":"Working Group on the Rheumatoid Arthritis-associated Lymphoproliferative Disorders of the Japan College of Rheumatology, Tokyo, Japan"},{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Kuramoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Working Group on the Rheumatoid Arthritis-associated Lymphoproliferative Disorders of the Japan College of Rheumatology, Tokyo, Japan"},{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Tokai University Hachioji Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Working Group on the Rheumatoid Arthritis-associated Lymphoproliferative Disorders of the Japan College of Rheumatology, Tokyo, Japan"},{"name":"Division of Rheumatology, Tokai University Hachioji Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"issue":"2","key":"2022010903465931300_R1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2022010903465931300_R2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis\u202f: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2022010903465931300_R3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3109\/14397595.2016.1141740","article-title":"Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: a nationwide cohort study in Japan","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"11","key":"2022010903465931300_R4","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00296-010-1524-0","article-title":"Incidence of malignancy in Japanese patients with rheumatoid arthritis","volume":"31","author":"Yamada","year":"2011","journal-title":"Rheumatol Int"},{"issue":"12","key":"2022010903465931300_R5","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.3899\/jrheum.150240","article-title":"Incidence and predictors of biological antirheumatic drug discontinuation attempts among patients with rheumatoid arthritis in remission: a CORRONA and NinJa collaborative cohort study","volume":"42","author":"Yoshida","year":"2015","journal-title":"J Rheumatol"},{"key":"2022010903465931300_R6","first-page":"443","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Immunodeficiency-associated lymphoproliferative disorders","author":"Swerdlow","year":"2017","edition":"Revised 4th ed."},{"key":"2022010903465931300_R7","author":"RHEUMATREX\u00ae CAPSULES","year":"2018"},{"issue":"4","key":"2022010903465931300_R8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3899\/jrheum.140533","article-title":"Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population","volume":"42","author":"Hashimoto","year":"2015","journal-title":"J Rheumatol"},{"key":"2022010903465931300_R9","first-page":"642","article-title":"Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents","volume":"26","author":"Katsuyama","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2022010903465931300_R10","first-page":"1","article-title":"Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders","volume":"27","author":"Nakano","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2022010903465931300_R11","first-page":"1860","article-title":"Report of the Committee on Hodgkin\u2019s disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"issue":"5","key":"2022010903465931300_R12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"2022010903465931300_R13","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/bjc.1998.163","article-title":"Soluble interleukin-2 receptors (sIL-2R) in Hodgkin\u2019s disease: outcome and clinical implications","volume":"77","author":"Viviani","year":"1998","journal-title":"Br J Cancer"},{"issue":"4","key":"2022010903465931300_R14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.clml.2013.03.014","article-title":"Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma","volume":"13","author":"Yoshizato","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2022010903465931300_R15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00277-001-0421-8","article-title":"Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma","volume":"81","author":"Wakao","year":"2002","journal-title":"Ann Hematol"},{"issue":"1","key":"2022010903465931300_R16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00432-008-0440-0","article-title":"Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)","volume":"135","author":"Kitagawa","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"2022010903465931300_R17","first-page":"5051","article-title":"Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma","volume":"32","author":"Yamauchi","year":"2012","journal-title":"Anticancer Res"},{"issue":"8","key":"2022010903465931300_R18","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/art.1780360807","article-title":"Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy","volume":"36","author":"Barrera","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2022010903465931300_R19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/emmm.201910576","article-title":"The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma","volume":"11","author":"Hashwah","year":"2019","journal-title":"EMBO Mol Med"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1080\/14397595.2020.1847775\/41812072\/1847775.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/1\/41\/42083480\/1847775.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/1\/41\/42083480\/1847775.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:55:40Z","timestamp":1642560940000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/1\/41-49\/6468896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,7]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1080\/14397595.2020.1847775","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2020,12,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imor20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imor20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}